151 related articles for article (PubMed ID: 24133297)
1. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses.
Fosdick A; Zheng J; Pflanz S; Frey CR; Hesselgesser J; Halcomb RL; Wolfgang G; Tumas DB
J Pharmacol Exp Ther; 2014 Jan; 348(1):96-105. PubMed ID: 24133297
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.
Lopatin U; Wolfgang G; Tumas D; Frey CR; Ohmstede C; Hesselgesser J; Kearney B; Moorehead L; Subramanian GM; McHutchison JG
Antivir Ther; 2013; 18(3):409-18. PubMed ID: 23416308
[TBL] [Abstract][Full Text] [Related]
4. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.
Gane EJ; Lim YS; Gordon SC; Visvanathan K; Sicard E; Fedorak RN; Roberts S; Massetto B; Ye Z; Pflanz S; Garrison KL; Gaggar A; Mani Subramanian G; McHutchison JG; Kottilil S; Freilich B; Coffin CS; Cheng W; Kim YJ
J Hepatol; 2015 Aug; 63(2):320-8. PubMed ID: 25733157
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
Lawitz E; Gruener D; Marbury T; Hill J; Webster L; Hassman D; Nguyen AH; Pflanz S; Mogalian E; Gaggar A; Massetto B; Subramanian GM; McHutchison JG; Jacobson IM; Freilich B; Rodriguez-Torres M
Antivir Ther; 2015; 20(7):699-708. PubMed ID: 25105516
[TBL] [Abstract][Full Text] [Related]
6. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
[TBL] [Abstract][Full Text] [Related]
7. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
Lanford RE; Guerra B; Chavez D; Giavedoni L; Hodara VL; Brasky KM; Fosdick A; Frey CR; Zheng J; Wolfgang G; Halcomb RL; Tumas DB
Gastroenterology; 2013 Jun; 144(7):1508-17, 1517.e1-10. PubMed ID: 23415804
[TBL] [Abstract][Full Text] [Related]
8. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.
Janssen HLA; Brunetto MR; Kim YJ; Ferrari C; Massetto B; Nguyen AH; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Yoshida EM; Ahn SH; Tsai NCS; Fung S; Gane EJ
J Hepatol; 2018 Mar; 68(3):431-440. PubMed ID: 29104121
[TBL] [Abstract][Full Text] [Related]
9. Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
Roethle PA; McFadden RM; Yang H; Hrvatin P; Hui H; Graupe M; Gallagher B; Chao J; Hesselgesser J; Duatschek P; Zheng J; Lu B; Tumas DB; Perry J; Halcomb RL
J Med Chem; 2013 Sep; 56(18):7324-33. PubMed ID: 23961878
[TBL] [Abstract][Full Text] [Related]
10. Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells.
Li L; Barry V; Daffis S; Niu C; Huntzicker E; French DM; Mikaelian I; Lanford RE; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):912-921. PubMed ID: 29247724
[TBL] [Abstract][Full Text] [Related]
11. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.
Boni C; Vecchi A; Rossi M; Laccabue D; Giuberti T; Alfieri A; Lampertico P; Grossi G; Facchetti F; Brunetto MR; Coco B; Cavallone D; Mangia A; Santoro R; Piazzolla V; Lau A; Gaggar A; Subramanian GM; Ferrari C
Gastroenterology; 2018 May; 154(6):1764-1777.e7. PubMed ID: 29378197
[TBL] [Abstract][Full Text] [Related]
12. Molecular Determinants of GS-9620-Dependent TLR7 Activation.
Rebbapragada I; Birkus G; Perry J; Xing W; Kwon H; Pflanz S
PLoS One; 2016; 11(1):e0146835. PubMed ID: 26784926
[TBL] [Abstract][Full Text] [Related]
13. TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells.
Bam RA; Hansen D; Irrinki A; Mulato A; Jones GS; Hesselgesser J; Frey CR; Cihlar T; Yant SR
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799218
[TBL] [Abstract][Full Text] [Related]
14. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7.
Boonstra A; Liu BS; Groothuismink ZM; Bergmann JF; de Bruijne J; Hotho DM; Hansen BE; van Vliet AA; van de Wetering de Rooij J; Fletcher SP; Bauman LA; Rahimy M; Appleman JR; Freddo JL; Reesink HW; de Knegt RJ; Janssen HL
Antivir Ther; 2012; 17(4):657-67. PubMed ID: 22301364
[TBL] [Abstract][Full Text] [Related]
15. TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation.
Enosi Tuipulotu D; Netzler NE; Lun JH; Mackenzie JM; White PA
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530841
[TBL] [Abstract][Full Text] [Related]
16. Activating the innate immune response to counter chronic hepatitis B virus infection.
Lamb C; Arbuthnot P
Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
[TBL] [Abstract][Full Text] [Related]
17. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells.
Abel K; Wang Y; Fritts L; Sanchez E; Chung E; Fitzgerald-Bocarsly P; Krieg AM; Miller CJ
Clin Diagn Lab Immunol; 2005 May; 12(5):606-21. PubMed ID: 15879022
[TBL] [Abstract][Full Text] [Related]
18. Negative regulation of the type I interferon signaling pathway by synthetic Toll-like receptor 7 ligands.
Forsbach A; Müller C; Montino C; Kritzler A; Nguyen T; Weeratna R; Jurk M; Vollmer J
J Interferon Cytokine Res; 2012 Jun; 32(6):254-68. PubMed ID: 22540943
[TBL] [Abstract][Full Text] [Related]
19. Expression of Toll like receptors 3 & 7 in peripheral blood from patients with chronic hepatitis C virus infection and their correlation with interferon-alpha.
Mohammed KI; Adel LA; Ali-Eldin FA; Eladawy S
Egypt J Immunol; 2013; 20(1):13-22. PubMed ID: 23888553
[TBL] [Abstract][Full Text] [Related]
20. An anti-interferon activity shared by paramyxovirus C proteins: inhibition of Toll-like receptor 7/9-dependent alpha interferon induction.
Yamaguchi M; Kitagawa Y; Zhou M; Itoh M; Gotoh B
FEBS Lett; 2014 Jan; 588(1):28-34. PubMed ID: 24269682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
